20
Disclosure:
Disclosure belangen spreker
I have no relevant financial or nonfinancial relationships to disclose.
The process to start action
• Create a dedicated task force of experts
• Analyse the epidemiological situation
• Analyse the financial aspects
• Select existing recommendations (e.g. WHO)
• Rank and prioritize first steps
• Establish a close monitoring of all activities
The process to start action
• Create a dedicated task force of experts
• Analyse the epidemiological situation
• Analyse the financial aspects
• Select existing recommendations (e.g. WHO)
• Rank and prioritize first steps
• Establish a close monitoring of all activities
Ministry of Health
Ministry of social affairs
Task Force
Task Force
Drug addiction doctors
epidemiologists
hepatologists
patients
Economic experts
Communication experts
Create a dedicated task force of experts
Task ForceInsurances
Public health experts
International experts
The process to start action
• Create a dedicated task force of experts
• Analyse the epidemiological situation
• Analyse the financial aspects
• Select existing recommendations (e.g. WHO)
• Rank and prioritize first steps
• Establish a close monitoring of all activities
Analyse the epidemiological situation
PreventionNumber of new infections
(risk groups, transmission routes)
Access tomedical care
Number of F0 – F2 patients
Targetedscreening
Number of undiagnosed(risk groups, transmission routes)
Urgent accesto treatment
Number of F3 – F4 patients
Urgent acces totreatment and
special care
Number of late stage patients(cirrhosis, decompensated cirrhosis,
cancer, serious extrahepaticmanifestations)
The process to start action
• Create a dedicated task force of experts
• Analyse the epidemiological situation
• Analyse the financial aspects
• Select existing recommendations (e.g. WHO)
• Rank and prioritize first steps
• Establish a close monitoring of all activities
model structure
HCV managementcosts (2015 Germany)
10
18 % of HCV Patient cause 80 % ofmedical management (without therapy costs)
41.579.220 €
39.462
51.473.685 €
4.437
98.243.791 €
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
HCV Patienten Gesundheitskosten
F0-F3 Zirrhose Spätfolgen
dia
gno
stiz
iert
151.220
Nic
ht
dia
gno
stiz
iert
97.855
Assumed change of diagnosis rates and treated patients(5.500 new infections / year)
11
Base Case Eliminationsszenario
-
50.000
100.000
150.000
200.000
250.000
300.000Anzahl
Patienten
Anzahl nicht-diagnostizierter Patienten
Anzahl diagnostizierter Patienten
Anzahl an Behandlungen
-
50.000
100.000
150.000
200.000
250.000
300.000
2015 2020 2025 2030 2035 2040
Anzahl Behandlungen
Anzahl nicht diagnostizierter Patienten
Anzahl diagnostizierter Patienten
Anzahl an Behandlungen
Presumed cost development: Base Case
12
Base Case• 250.000 persons infected with HCV, of whom are 60 are diagnosed• 25.000 annual treatment with INF-free DAAs • 5.500 new infections per year• No targeted screening
0
500
1.000
1.500
2.000
2.500
2015 2020 2025 2030 2035 2040
Mill
ion
en
€
Gesundheitskosten Indirekte Kosten Behandlungskosten
Presumed cost development: elimination scenario
13
Elimination scenario:• 250.000 persons infected with HCV of whom 60% are diagnosed• 25.000 annual treatments with INF-free DAAs• No new infections• Non-diagnosed patients are identified by targeted screening
0
500
1.000
1.500
2.000
2.500
2015 2020 2025 2030 2035 2040
Mill
ion
en
€
Gesundheitskosten Indirekte Kosten Behandlungskosten Screening Kosten
Overall costs development
Base Case Eliminationsszenario Differenz
2015 - 2019 8.258.574.799 € 9.316.658.012 € 1.058.083.213 €
2020 - 2024 2.665.606.224 € 4.529.801.427 € 1.864.195.203 €
2025 - 2029 952.221.025 € 257.553.982 € - 694.667.043 €
2030 - 2034 711.809.749 € 104.430.693 € - 607.379.056 €
2035 - 2040 628.178.835 € 66.509.935 € - 561.668.900 €
2015 - 2040 13.216.390.632 € 14.274.954.049 € 1.058.563.417 €
0
500
1.000
1.500
2.000
2.500
Mill
ion
en
€
Base Case Eliminationsszenario
The process to start action
• Create a dedicated task force of experts
• Analyse the epidemiological situation
• Analyse the financial aspects
• Select existing recommendations (e.g. WHO, INHSU, ELPA, WHA, HBCPPA)
• Rank and prioritize first steps
• Establish a close monitoring of all activities
The “Macro Paper”
The process to start action
• Create a dedicated task force of experts
• Analyse the epidemiological situation
• Analyse the financial aspects
• Select existing recommendations (e.g. WHO, INHSU, ELPA, WHA, HBCPPA)
• Rank and prioritize first steps
• Establish a close monitoring of all activities
The process to start action
• Create a dedicated task force of experts
• Analyse the epidemiological situation
• Analyse the financial aspects
• Select existing recommendations (e.g. WHO, INHSU, ELPA, WHA, HBCPPA)
• Rank and prioritize first steps
• Establish a close monitoring of all activities
The key factor of a successfull strategy:
• The patient!
You have everything to start saving lifes now
Let’s start !
